About city therapeutics inc - CTY
City Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the development of RNAi therapeutics. The company was founded by John Maraganore, Sebastian Trousil, Ari Nowacek, Mark Keating, Kotaro Nakanishi, Yukihide Tomari, and Phillip Zamore on July 17, 2023 and is headquartered in Cambridge, MA.
CTY At a Glance
City Therapeutics, Inc.
399 Binney Street
Cambridge, Massachusetts 02142
| Phone | 1-857-357-2024 | Revenue | 13.56M | |
| Industry | Pharmaceuticals: Major | Net Income | -58,505,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 388.193% | |
| Fiscal Year-end | 12 / 2026 | Employees | N/A | |
| View SEC Filings |
CTY Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
CTY Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 11.218 |
| Total Asset Turnover | 0.092 |
CTY Liquidity
| Current Ratio | 3.072 |
| Quick Ratio | 3.072 |
| Cash Ratio | 2.965 |
CTY Profitability
| Gross Margin | 91.358 |
| Operating Margin | -441.837 |
| Pretax Margin | -431.389 |
| Net Margin | -431.389 |
| Return on Assets | -39.648 |
| Return on Equity | N/A |
| Return on Total Capital | -46.015 |
| Return on Invested Capital | -49.732 |
CTY Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 166.583 |
| Total Debt to Total Assets | 141.417 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 154.093 |